和黃醫藥(00013.HK)公佈中期業績:總收入增長47%至1.574億美元,繼續建立美國商業團隊
格隆匯7月28日丨和黃醫藥(00013.HK)公佈中期業績,2021年上半年,總收入增長47%至1.574億美元;腫瘤/免疫業務綜合收入增長161%至4,290萬美元。公司的中國腫瘤商業團隊規模已擴大至約540名員工(2020年底:約390名),覆蓋2,500多家腫瘤醫院和逾29,000名腫瘤科醫生。
愛優特®(呋喹替尼的中國商品名)的市場銷售額增長186%至4,010萬美元-,反映和黃醫藥團隊在中國加強的醫學訊息溝通、市場推廣以及本地和區域活動。
蘇泰達®(索凡替尼的中國商品名)上市,用於治療胰腺外神經內分泌瘤(NET16)(2021年1月中)及胰腺神經內分泌瘤(2021年6月),銷售額為800萬美元(2020年上半年:零)。
沃瑞沙®(賽沃替尼)於獲批後三週內透過阿斯利康龐大、市場領先腫瘤商業團隊於2021年7月上市。和黃醫藥將根據中國的所有銷售額收取30%的固定特許權使用費;及繼續建立美國商業團隊,索凡替尼可能於2022年上半年在美國獲得批准。該團隊正全力籌備各方面的上市準備工作,包括供應鏈、市場準入、市場營銷、銷售和商業營運。
和黃醫藥主席杜志強表示:"和黃醫藥取得非常出色的進展。我們的創新藥物發現及開發引擎保持快速發展。我們不僅在中國迎來了的第三和第四個創新腫瘤藥物的 NDA4獲批,我們向 FDA5及 EMA6提交的上市申請亦獲受理。"
"基於在單藥及免疫療法/TKI7聯合療法概念驗證研究中取得令人鼓舞的數據,我們五個全球領先創新藥物的十項註冊研究將在今年開始。此外,早期階段的產品管綫包括 IDH1/28、ERK9及第三代 BTK10抑制劑均於今年開始臨牀開發。"
"未來三年,我們將繼續迅速建立我們的全球研發15及商業團隊,以支援我們多個創新腫瘤藥物的預期全球上市。"
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.